Reneo reports Q4 2022 net loss $13.6M; STRIDE study enrollment complete

OnKure Therapeutics, Inc.

Full-year 2022 net loss $52.0M ($2.12 per share) vs $39.8M loss in 2021.
Cash, equivalents & short-term investments $101.2M as of Dec 31, 2022.
R&D expenses $37.7M in 2022, up 34% due to STRIDE and STRIDE AHEAD studies.
Pivotal STRIDE study (PMM) enrolled target 200 patients; topline results expected Q4 2023.
Plans to study mavodelpar in PMM due to nDNA defects and advance LC-FAOD program into Phase 2.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OnKure Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022.

Period: the fourth quarter and year ended December 31, 2022
Net income: net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022
Result: reported results

Exact text from the filing

We reported a net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022, compared to a net loss of $10.6 million, or $0.43 per share, for the same period in 2021. For the full year 2022, we reported a net loss of $52.0 million, or $2.12 per share, compared to a net loss of $39.8 million, or $2.19 per share, for the full year 2021.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.